Spyre Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary

Spyre Therapeutics

08/11/2024 05:11

* Spyre Therapeutics Inc  SYRE.OQ  reported a quarterly
adjusted
loss of $1.36​​ per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of $-9.34.  The mean expectation of nine analysts
for the quarter was for a loss of 82 cents per share. Wall
Street expected results to range from $-1.05 to -45 cents per
share.
    * Reported revenue was zero​; analysts expected zero. 
    * Spyre Therapeutics Inc's reported EPS for the quarter was
a loss
of $1.36​.
    * The company reported a quarterly loss of $69.03 million.
    * Spyre Therapeutics Inc shares had risen by 27.4% this
quarter and gained 74.2% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 7.2%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 9 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "strong buy"

Wall Street's median 12-month price target for Spyre
Therapeutics Inc is $47.50 
This summary was machine generated from LSEG data November 8 at
05:11 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.82          -1.36          Missed
 Jun. 30 2024      -0.95          -0.86          Beat
 Mar. 31 2024      -1.17          -1.20          Missed
 Dec. 31 2023      -0.78          -4.05          Missed